Great opportunity to share and discuss cutting-edge approaches/aspects in drug discovery.
Fabrizio G., Principal Scientist, AstraZeneca
Epigenetic drug discovery is one of the fastest growing and potentially groundbreaking target spaces for developers. Over the past few years, a significant increase in small molecule inhibitors chemically modulating enzymatic activity of Histone Methyltransferases (HMTs), Histone Demethylases (HDMs), and disrupting interactions of the BET family bromodomains have rapidly translated into clinical investigation. Now, with apparent safety and efficacy being demonstrated in clinical trials, the opportunity to develop novel chemical tools and inhibitors against the wealth of epigenetic modifiers is ever present.
Cambridge Healthtech Institute will once again convene leaders in Epigenetic Inhibitor Discovery to bring forth novel and emerging strategies for inhibition, new bioactive tools and inhibitors, as well as strategies for lead optimization to obtain clinically relevant small molecules. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of CHI’s larger Drug Discovery Chemistry event.
Featured Presentation: A Bump-and-Hole Approach to Engineer Controlled Selectivity of BET Bromodomain Chemical Probes
Alessio Ciulli, Ph.D., Reader, Chemical & Structural Biology, BBSRC David Phillips Fellow, College of Life Sciences, University of Dundee
Discovery of Dual PI3K/BRD4 Inhibitors
Donald Durden, M.D., Ph.D., Professor, Vice Chair, Pediatrics, UCSD School of Medicine; CEO and President, SignalRx Pharmaceuticals
Discovery and Development of a Potent Dual TRIM24/BRPF1 Inhibitor, IACS-9571, Using Structure-Based Drug Design
Wylie Palmer, Ph.D., Institute Research Scientist, Institute of Applied Cancer Science, MD Anderson Cancer Center
Discovery and Development of Novel BET Bromodomain Inhibitors
Brian Albrecht, Ph.D., Senior Director, Medicinal Chemistry, Constellation Pharmaceuticals
Discovery of Novel Small Molecules and Small Cyclic Peptides as Chemical Tools and Inhibitors, Using DNA Encoded Peptide Libraries for HDMs and HMTs
Brian Lohse, Ph.D., Associate Professor, Drug Design and Pharmacology, University of Copenhagen
In silico Discovery and Experimental Validation of Selective Bromodomain Inhibitors
Amedeo Caflisch, Ph.D., Professor and Chair, Computational Structural Biology, Department of Biochemistry, University of Zurich
The Discovery and Characterization of A-366, a Potent and Selective Inhibitor of Histone Methyltransferase G9a
Ramzi Sweis, Ph.D., Research Investigator, Discovery Chemistry, AbbVie, Inc.
Discovery of Novel Inhibitors of Histone H3-Lysine79 (H3K79) Methyltransferase DOT1L
Yongcheng Song, Ph.D., Associate Professor, Pharmacology, Baylor College of Medicine
Discovery and Development of Novel Arginine Methyltransferase Inhibitors
Richard Chesworth, Ph.D., Epizyme
Discovery of a Potent and Specific Drug to Inhibit PRMT5 in Hematologic and Solid Tumors
Chenglong Li, Ph.D., Associate Professor, Division of Medicinal Chemistry and Pharmacognosy College of Pharmacy, The Ohio State University Comprehensive Cancer Center
For more details on the conference, please contact:
Cambridge Healthtech Institute
Phone: (+1) 781-972-5454
For partnering and sponsorship information, please contact:
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412